RTC
RPRX icon

Riverview Trust Company’s Royalty Pharma RPRX Stock Holding History

Riverview Trust Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,216
Closed -$37.9K – 516
2025
Q1 		$37.9K Hold
1,216
– – 0.04% 265
2024
Q4 		$31K Buy
1,216
+1,186
+3,953% +$31.4K 0.03% 303
2024
Q3 		$849 Buy
+30
New +$831 ﹤0.01% 666
2023
Q1 		– Sell
-527
Closed -$21K – 729
2022
Q4 		$21K Hold
527
– – 0.02% 333
2022
Q3 		$21K Hold
527
– – 0.02% 359
2022
Q2 		$22K Hold
527
– – 0.02% 368
2022
Q1 		$21K Buy
+527
New +$20.7K 0.02% 479

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Riverview Trust Company's RPRX Position: Q2 2025 in Review

Riverview Trust Company sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 1,216 shares — an estimated $37.9K sold.

Riverview Trust Company first reported a position in RPRX in Q1 2022 and held it in 7 quarters. The position peaked at $37.9K in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Riverview Trust Company reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Riverview Trust Company sold 1,216 Royalty Pharma shares in Q2 2025, an estimated $37.9K.
  • Riverview Trust Company first reported a position in Royalty Pharma in Q1 2022 and held it in 7 quarters.
  • Riverview Trust Company's Royalty Pharma position peaked at $37.9K in Q1 2025.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.